Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2025 Guidance
Arteris (Nasdaq: AIP), a semiconductor system IP provider, reported its Q2 2025 financial results and updated guidance. The company achieved record Annual Contract Value plus royalties of $69.1 million and Remaining Performance Obligations of $99.3 million, up 28% year-over-year.
Q2 2025 highlights include revenue of $16.5 million (up 13% YoY), operating loss of $8.2 million, and net loss of $9.1 million ($0.22 per share). Business achievements include AMD licensing FlexGen IP, a Whalechip AI win, expanded multi-die solutions, and an AI Breakthrough Award for FlexGen.
For Q3 2025, Arteris expects ACV + royalties of $69.5-72.5 million and revenue of $16.8-17.2 million. Full year 2025 guidance projects revenue of $66.0-70.0 million.
Arteris (Nasdaq: AIP), fornitore di IP per sistemi semiconduttori, ha comunicato i risultati finanziari del secondo trimestre 2025 e aggiornato le previsioni. L'azienda ha raggiunto un valore contrattuale annuale più royalty record di 69,1 milioni di dollari e obblighi di prestazione residui pari a 99,3 milioni di dollari, con un incremento del 28% rispetto all'anno precedente.
I punti salienti del Q2 2025 includono un fatturato di 16,5 milioni di dollari (in crescita del 13% su base annua), una perdita operativa di 8,2 milioni e una perdita netta di 9,1 milioni di dollari (0,22 dollari per azione). Tra i successi aziendali si annoverano la licenza FlexGen IP concessa ad AMD, una vittoria con Whalechip AI, l'espansione delle soluzioni multi-die e il premio AI Breakthrough per FlexGen.
Per il Q3 2025, Arteris prevede un ACV più royalty tra 69,5 e 72,5 milioni di dollari e un fatturato tra 16,8 e 17,2 milioni. Le previsioni per l'intero anno 2025 indicano un fatturato compreso tra 66,0 e 70,0 milioni di dollari.
Arteris (Nasdaq: AIP), proveedor de IP para sistemas de semiconductores, informó sus resultados financieros del segundo trimestre de 2025 y actualizó sus previsiones. La compañía alcanzó un valor contractual anual más regalías récord de 69,1 millones de dólares y obligaciones de desempeño pendientes de 99,3 millones de dólares, un aumento del 28% interanual.
Los aspectos destacados del Q2 2025 incluyen ingresos de 16,5 millones de dólares (un aumento del 13% interanual), una pérdida operativa de 8,2 millones y una pérdida neta de 9,1 millones de dólares (0,22 dólares por acción). Entre los logros comerciales se encuentran la concesión de licencia de FlexGen IP a AMD, una victoria con Whalechip AI, la expansión de soluciones multi-die y el premio AI Breakthrough para FlexGen.
Para el Q3 2025, Arteris espera un ACV más regalías de entre 69,5 y 72,5 millones de dólares y unos ingresos de entre 16,8 y 17,2 millones. La guía para todo el año 2025 proyecta ingresos de entre 66,0 y 70,0 millones de dólares.
Arteris (나스�: AIP)� 반도� 시스� IP 제공업체로서 2025� 2분기 재무 실적� 업데이트� 가이던스를 발표했습니다. 회사� 연간 계약 가� � 로열� 합계 6,910� 달러왶 잔여 성과 의무 9,930� 달러� 기록하며 전년 대� 28% 증가했습니다.
2025� 2분기 주요 내용으로� 매출 1,650� 달러(전년 대� 13% 증가), 영업 손실 820� 달러, 순손� 910� 달러(주당 0.22달러)가 포함됩니�. 사업 성과로는 AMD� FlexGen IP 라이선스, Whalechip AI 수주, 다이 통합 솔루� 확장, FlexGen� 대� AI Breakthrough Award 수상� 있습니다.
2025� 3분기에는 Arteris가 ACV � 로열� 6,950만~7,250� 달러, 매출 1,680만~1,720� 달러� 예상합니�. 2025� 전체 연간 가이던스는 매출 6,600만~7,000� 달러� 전망합니�.
Arteris (Nasdaq : AIP), fournisseur de propriété intellectuelle pour systèmes semi-conducteurs, a publié ses résultats financiers du deuxième trimestre 2025 et mis à jour ses prévisions. La société a atteint une valeur contractuelle annuelle plus redevances record de 69,1 millions de dollars et des obligations de performance restantes de 99,3 millions de dollars, en hausse de 28 % par rapport à l'année précédente.
Les points forts du T2 2025 incluent un chiffre d'affaires de 16,5 millions de dollars (en hausse de 13 % en glissement annuel), une perte d'exploitation de 8,2 millions et une perte nette de 9,1 millions de dollars (0,22 dollar par action). Parmi les réussites commerciales figurent la licence FlexGen IP accordée à AMD, un succès avec Whalechip AI, l'expansion des solutions multi-die et un prix AI Breakthrough pour FlexGen.
Pour le T3 2025, Arteris prévoit un ACV plus redevances entre 69,5 et 72,5 millions de dollars et un chiffre d'affaires entre 16,8 et 17,2 millions. Les prévisions pour l'année complète 2025 projettent un chiffre d'affaires entre 66,0 et 70,0 millions de dollars.
Arteris (Nasdaq: AIP), ein Anbieter von IP-Systemen für Halbleiter, berichtete über seine Finanzergebnisse für das zweite Quartal 2025 und aktualisierte die Prognosen. Das Unternehmen erzielte einen rekordverdächtigen jährlichen Vertragswert zuzüglich Lizenzgebühren von 69,1 Millionen US-Dollar und verbleibende Leistungsverpflichtungen von 99,3 Millionen US-Dollar, was einem Anstieg von 28 % gegenüber dem Vorjahr entspricht.
Zu den Highlights des zweiten Quartals 2025 gehören ein Umsatz von 16,5 Millionen US-Dollar (ein Plus von 13 % gegenüber dem Vorjahr), ein operativer Verlust von 8,2 Millionen und ein Nettoverlust von 9,1 Millionen US-Dollar (0,22 US-Dollar pro Aktie). Zu den geschäftlichen Erfolgen zählen die Lizenzierung der FlexGen-IP an AMD, ein Auftrag von Whalechip AI, erweiterte Multi-Die-Lösungen und ein AI Breakthrough Award für FlexGen.
Für das dritte Quartal 2025 erwartet Arteris einen ACV plus Lizenzgebühren von 69,5 bis 72,5 Millionen US-Dollar und einen Umsatz von 16,8 bis 17,2 Millionen US-Dollar. Die Prognose für das Gesamtjahr 2025 sieht einen Umsatz von 66,0 bis 70,0 Millionen US-Dollar vor.
- Record Annual Contract Value plus royalties of $69.1M, up 15% YoY
- RPO grew to highest level ever at $99.3M, up 28% YoY
- Revenue increased 13% YoY to $16.5M
- Secured major customer wins including AMD and Whalechip for AI applications
- Won AI Engineering Innovation Award for FlexGen technology
- Operating loss increased to $8.2M from $7.4M in Q2 2024
- Net loss of $9.1M ($0.22 per share)
- Non-GAAP operating loss remained flat at $3.5M
Insights
Arteris reports strong Q2 growth with record ACV and RPO despite continued losses, showing improving business momentum in AI and chiplet markets.
Arteris delivered solid growth in Q2 2025, with revenue increasing
Despite the top-line growth, Arteris continues to operate at a loss, with operating losses widening slightly to
The business highlights reveal Arteris' strategic positioning in high-growth semiconductor markets, particularly AI and multi-die/chiplet solutions. Landing AMD as a customer for their FlexGen network-on-chip IP for AI chiplets represents a significant win. The company is also expanding its presence in data center AI with Whalechip and broadening its multi-die solution portfolio through ecosystem partnerships with major players like Synopsys, Cadence, and RISC-V partners.
Looking forward, management provided Q3 guidance for ACV plus royalties of
CAMPBELL, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor system IP for accelerating system-on-chip (SoC) creation, today announced financial results for the second quarter ended June30, 2025 and provided estimated third quarter and updated full year 2025 guidance.
“In the second quarter of 2025, we achieved record Annual Contract Value plus royalties of
Second Quarter 2025 Financial Highlights:
- Revenue of
$16.5 million , up13% year-over-year - Annual Contract Value (ACV) plus royalties of
$69.1 million , up15% year-over-year, growing to the highest level we have ever reported - Remaining performance obligation (RPO) of
$99.3 million , up28% year-over-year, growing to the highest level we have ever reported - Operating loss of
$8.2 million , compared to an operating loss of$7.4 million in the second quarter of 2024 - Non-GAAP operating loss of
$3.5 million , flat compared to a Non-GAAP operating loss of$3.5 million in the second quarter of 2024 - Net loss of
$9.1 million or$0.22 per share - Non-GAAP net loss of
$4.4 million or$0.11 per share
Second Quarter 2025 Business Highlights:
- AMD licensed FlexGen smart network-on-chip IP to provide high-performance data transport for its chiplets powering AI, targeting a broad array of products;
- Announced a key customer AI win, Whalechip, that is licensing FlexNoC 5 for its high-performance AI computing at the data center;
- Expanded Arteris' multi-die solution, broadening the support for the Universal Chiplet Interconnect Express (UCIe), extended support for Arm AMBA protocols, collaborating with Synopsys and Cadence for chiplet interface, and supporting RISC-V ecosystems with partners such as Andes, SiFive, and Tenstorrent;
- Announced Magillem Packaging, a new software product designed to automate IP packaging, thereby simplifying and accelerating chiplet and SoC assembly; and
- Arteris was recognized in the 8th annual AI Breakthrough Awards, with FlexGen winning the “AI Engineering Innovation Award�.
Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP operating loss, Non-GAAP operating loss margin, Non-GAAP net loss, Non-GAAP net loss per share, and free cash flow are Non-GAAP financial measures. Additional information on Arteris� historic reported results, including a reconciliation of these Non-GAAP financial measures to their most comparable GAAP measures, is included in the financial tables below.
Estimated Third Quarter and Updated Full Year 2025 Guidance:
Q3 2025 | FY 2025 | |
(in millions) | ||
ACV + royalties | ||
Revenue | ||
Non-GAAP operating loss | ||
Free cash flow | ||
The guidance provided above are forward-looking statements and reflects Arteris' expectations as of today's date. Actual results may differ materially. Refer to the section titled "Forward-Looking Statements" below for information on the factors, among others, that could cause our actual results to differ materially from these forward-looking statements.
A reconciliation of Non-GAAP guidance measures reported above to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Arteris' results computed in accordance with GAAP.
Definitions of the other business metrics used in this press release including ACV, confirmed design starts and RPO are included below under the heading “Other Business Metrics.�
Conference Call
Arteris will host a conference call on August5, 2025 to review its second quarter 2025 financial results and to discuss its financial outlook.
Time: | 4:30PM ET | |
United States/Canada Toll Free: | 1-800-717-1738 | |
International Toll: | 1-646-307-1865 | |
A live webcast will also be available in the Investor Relations section of Arteris� website at: https://ir.arteris.com/events-and-presentations
A replay of the webcast will be available in the Investor Relations section of Arteris' website approximately two hours after the conclusion of the call and remain available for approximately 30 calendar days.
About Arteris
Arteris is a global leader in system IP used in semiconductors to accelerate the creation of high-performance, power-efficient silicon. Arteris network-on-chip (NoC) interconnect IP and system-on-chip (SoC) integration automation software are used by the world's top semiconductor and technology companies to improve overall performance, engineering productivity, reduce risk, lower costs, and bring complex designs to market faster. Learn more at arteris.com.
© 2004-2025 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.
Investor Contacts:
Arteris
Nick Hawkins
Chief Financial Officer
[email protected]
Sapphire Investor Relations, LLC
Erica Mannion and Michael Funari
+1 617 542 6180
[email protected]
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but not limited to, statements regarding our long-term growth opportunity and future financial and operating performance, including our GAAP and Non-GAAP estimated third quarter and updated full year 2025 guidance. The words such as "may," "will," "could," "expect," "approximately," "believe," "estimate," "future," "guidance," "outlook," and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained herein are based on our historical performance and our current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent our expectations as of the date of this press release. Subsequent events may cause these expectations to change, and we disclaim any obligation to update the forward-looking statements in the future, except as required by law. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from our current expectations. Important factors that could cause actual results to differ materially from those anticipated in our forward-looking statements include, but are not limited to, the significant competition we face from larger companies and third-party providers; our history of net losses; whether semiconductor companies in the automotive market, enterprise computing market, communications market, consumer electronics market, and industrial markets incorporate our solutions into their end products and the growth and economic stability of these end markets; our ability to attract new customers and the extent to which our customers renew their subscriptions for our solutions; the ability of our customers� end products achieving market acceptance or growth; our ability to sustain or grow our licensing revenue; our ability, and the cost, to successfully execute on research and development efforts; the occurrence of product errors or defects in our solutions; if we fail to offer high-quality support; the occurrence of macro-economic conditions that adversely impact us, our customers and their end product markets including, but not limited to, the imposition of tariffs in markets where we operate; the effects of geopolitical conflicts, such as the military conflict between Russia and Ukraine as well as the ongoing conflict in the Middle East; the range of regulatory, operational, financial and political risks we are exposed to as a result of our dependence on international customers and operations; our ability to protect our proprietary technology and inventions through patents and other IP rights; whether we are subject to any liabilities or fines as a result of government regulation, including import, export and economic sanctions laws and regulations; the occurrence of a disruption in our networks or a security breach; risks associated with doing business in China, including as a result of changes to trade relations between the United States and China; and the other factors described under the heading “Risk Factors� in our Quarterly Report on Form 10-Q for the quarter ended June30, 2025 to be filed with the Securities and Exchange Commission (SEC) on August5, 2025. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. Our results for the quarter ended June30, 2025 are not necessarily indicative of our operating results for any future periods.
Arteris, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Revenue | |||||||||||||||
Licensing, support and maintenance | $ | 15,088 | $ | 13,553 | $ | 30,423 | $ | 25,292 | |||||||
Variable royalties and other | 1,414 | 1,022 | 2,611 | 2,230 | |||||||||||
Total revenue | 16,502 | 14,575 | 33,034 | 27,522 | |||||||||||
Cost of revenue | 1,742 | 1,458 | 3,268 | 2,926 | |||||||||||
Gross profit | 14,760 | 13,117 | 29,766 | 24,596 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 12,171 | 10,717 | 24,033 | 21,552 | |||||||||||
Sales and marketing | 6,335 | 5,013 | 12,864 | 10,469 | |||||||||||
General and administrative | 4,502 | 4,828 | 8,825 | 9,150 | |||||||||||
Total operating expenses | 23,008 | 20,558 | 45,722 | 41,171 | |||||||||||
Loss from operations | (8,248 | ) | (7,441 | ) | (15,956 | ) | (16,575 | ) | |||||||
Interest expense | (42 | ) | (68 | ) | (90 | ) | (144 | ) | |||||||
Other income (expense), net | 786 | 865 | 1,504 | 1,801 | |||||||||||
Loss before income taxes and loss from equity method investment | (7,504 | ) | (6,644 | ) | (14,542 | ) | (14,918 | ) | |||||||
Loss from equity method investment, net of tax | 780 | 725 | 1,595 | 1,484 | |||||||||||
Provision for income taxes | 846 | 975 | 1,114 | 1,345 | |||||||||||
Net loss | $ | (9,130 | ) | $ | (8,344 | ) | $ | (17,251 | ) | $ | (17,747 | ) | |||
Net loss per share attributable to common stockholders, basic | $ | (0.22 | ) | $ | (0.22 | ) | $ | (0.42 | ) | $ | (0.47 | ) | |||
Weighted-average shares used in computing per share amounts, basic and diluted | 41,819,427 | 38,476,934 | 41,338,907 | 38,092,996 |
Arteris, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) | |||||||
As of | |||||||
June 30, | December 31, | ||||||
2025 | 2024 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 16,100 | $ | 13,684 | |||
Short-term investments | 21,857 | 30,157 | |||||
Accounts receivable, net of allowance of | 18,753 | 20,608 | |||||
Prepaid expenses and other current assets | 4,833 | 4,634 | |||||
Total current assets | 61,543 | 69,083 | |||||
Property and equipment, net | 4,290 | 4,019 | |||||
Long-term investments | 15,905 | 8,504 | |||||
Equity method investment | 4,207 | 5,802 | |||||
Operating lease right-of-use assets | 4,430 | 3,838 | |||||
Intangibles, net | 2,582 | 3,024 | |||||
Goodwill | 4,178 | 4,178 | |||||
Other assets | 9,745 | 7,687 | |||||
TOTAL ASSETS | $ | 106,880 | $ | 106,135 | |||
LIABILITIES AND STOCKHOLDERS� DEFICIT | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 856 | $ | 539 | |||
Accrued expenses and other current liabilities | 15,321 | 15,899 | |||||
Operating lease liabilities, current | 1,106 | 917 | |||||
Deferred revenue, current | 43,321 | 40,445 | |||||
Vendor financing arrangements, current | 1,955 | 1,482 | |||||
Total current liabilities | 62,559 | 59,282 | |||||
Deferred revenue, noncurrent | 38,626 | 35,177 | |||||
Operating lease liabilities, noncurrent | 3,733 | 2,998 | |||||
Vendor financing arrangements, noncurrent | 563 | 594 | |||||
Deferred income, noncurrent | 7,046 | 7,631 | |||||
Other liabilities | 1,882 | 1,641 | |||||
Total liabilities | 114,409 | 107,323 | |||||
Stockholders' deficit: | |||||||
Preferred stock, par value of | � | � | |||||
Common stock, par value of | 42 | 40 | |||||
Additional paid-in capital | 146,350 | 135,522 | |||||
Accumulated other comprehensive income | 215 | 135 | |||||
Accumulated deficit | (154,136 | ) | (136,885 | ) | |||
Total stockholders' deficit | (7,529 | ) | (1,188 | ) | |||
TOTAL LIABILITIES AND STOCKHOLDERS� DEFICIT | $ | 106,880 | $ | 106,135 |
Arteris, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) | |||||||
Six Months Ended June 30, | |||||||
2025 | 2024 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net loss | $ | (17,251 | ) | $ | (17,747 | ) | |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
Depreciation and amortization | 1,689 | 1,630 | |||||
Stock-based compensation | 8,809 | 7,417 | |||||
Amortization of deferred income | (585 | ) | (588 | ) | |||
Loss from equity method investment | 1,595 | 1,484 | |||||
Net accretion of discounts on available-for-sale securities | (221 | ) | (344 | ) | |||
Other, net | 378 | 24 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 1,855 | 3,055 | |||||
Prepaid expenses and other assets | (2,261 | ) | 865 | ||||
Accounts payable | 319 | 156 | |||||
Accrued expenses and other liabilities | (277 | ) | 103 | ||||
Deferred revenue | 6,325 | 4,733 | |||||
Net cash provided by operating activities | 375 | 788 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Purchases of property and equipment | (538 | ) | (243 | ) | |||
Purchases of available-for-sale securities | (17,160 | ) | (12,981 | ) | |||
Proceeds from maturities of available-for-sale securities and other | 18,282 | 20,769 | |||||
Net cash provided by investing activities | 584 | 7,545 | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Principal payments under vendor financing arrangements | (558 | ) | (485 | ) | |||
Proceeds from exercise of stock options | 1,452 | 584 | |||||
Proceeds from employee stock purchase plan | 535 | � | |||||
Other financing activities | 27 | � | |||||
Net cash provided by financing activities | 1,456 | 99 | |||||
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 2,415 | 8,432 | |||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period | 14,072 | 14,084 | |||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period | $ | 16,487 | $ | 22,516 | |||
Non-GAAP Financial Measures
To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors� overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We define "Non-GAAP gross profit" and "Non-GAAP gross margin" as GAAP gross profit and GAAP gross margin, respectively, adjusted for stock-based compensation expense included in cost of revenue and amortization of acquired intangible assets included in cost of revenue. We define “Non-GAAP loss from operations� as our GAAP loss from operations adjusted to exclude stock-based compensation expense and amortization of acquired intangible assets. We define “Non-GAAP net loss� as our net loss adjusted to exclude stock-based compensation and amortization of acquired intangible assets.
We define “Non-GAAP net loss per share attributable to common stockholders, basic and diluted�, as our Non-GAAP net loss divided by our GAAP weighted-average number of shares outstanding for the period on a basic or diluted basis, respectively. Management uses this non-GAAP measure to evaluate the performance of our business on a comparable basis from period to period.
The above items are excluded from our Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP gross profit, Non-GAAP loss from operations and Non-GAAP net loss provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance.
We define free cash flow as net cash provided by operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash used in our operations other than that used for investments in property and equipment.
Other Business Metrics
Annual Contract Value (ACV) � we define Annual Contract Value for an individual customer agreement as the total fixed fees under the agreement divided by the number of years in the agreement term. Our total ACV is the aggregate ACVs for all our customers as measured at a given point in time. Total fixed fees includes licensing, support and maintenance and other fixed fees under IP licensing or software licensing agreements but excludes variable revenue derived from licensing agreements with customers, particularly royalties. We define ACV plus royalties as ACV plus the trailing-twelve-months variable royalties and other revenue.
Confirmed Design Starts � we define Confirmed Design Starts as when customers confirm their commencement of new semiconductor designs using our interconnect IP and notify us. Confirmed Design Starts is a metric management uses to assess the activity level of our customers in terms of the number of new semiconductor designs that are started using our interconnect IP in a given period. We believe that the number of Confirmed Design Starts is an important indicator of the growth of our business and future royalty revenue trends.
Remaining Performance Obligations (RPO) � we define Remaining Performance Obligations as the amount of contracted future revenue that has not yet been recognized, including deferred revenue, billed and unbilled cancelable and non-cancelable contracted amounts.
Arteris, Inc. Reconciliation of GAAP Measures to Non-GAAP Measures (In thousands, except share and per share data) (Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Gross profit | $ | 14,760 | $ | 13,117 | $ | 29,766 | $ | 24,596 | |||||||
Add: | |||||||||||||||
Stock-based compensation expense included in cost of revenue | 232 | 186 | 437 | 375 | |||||||||||
Amortization of acquired intangible assets (1) | 50 | 50 | 100 | 100 | |||||||||||
Non-GAAP gross profit | $ | 15,042 | $ | 13,353 | $ | 30,303 | $ | 25,071 | |||||||
Gross margin | 89 | % | 90 | % | 90 | % | 89 | % | |||||||
Non-GAAP gross margin | 91 | % | 92 | % | 92 | % | 91 | % | |||||||
Research and development | $ | 12,171 | $ | 10,717 | $ | 24,033 | $ | 21,552 | |||||||
Stock-based compensation expense | (1,926 | ) | (1,788 | ) | (3,898 | ) | (3,396 | ) | |||||||
Amortization of acquired intangible assets (1) | (110 | ) | (85 | ) | (220 | ) | (170 | ) | |||||||
Non-GAAP research and development | $ | 10,135 | $ | 8,844 | $ | 19,915 | $ | 17,986 | |||||||
Sales and marketing | $ | 6,335 | $ | 5,013 | $ | 12,864 | $ | 10,469 | |||||||
Stock-based compensation expense | (1,048 | ) | (657 | ) | (2,017 | ) | (1,380 | ) | |||||||
Amortization of acquired intangible assets (1) | (57 | ) | (57 | ) | (114 | ) | (114 | ) | |||||||
Non-GAAP sales and marketing | $ | 5,230 | $ | 4,299 | $ | 10,733 | $ | 8,975 | |||||||
General and administrative | $ | 4,502 | $ | 4,828 | $ | 8,825 | $ | 9,150 | |||||||
Stock-based compensation expense | (1,291 | ) | (1,129 | ) | (2,457 | ) | (2,266 | ) | |||||||
Non-GAAP general and administrative | $ | 3,211 | $ | 3,699 | $ | 6,368 | $ | 6,884 | |||||||
Total operating expenses | $ | 23,008 | $ | 20,558 | $ | 45,722 | $ | 41,171 | |||||||
Stock-based compensation expense | (4,265 | ) | (3,574 | ) | (8,372 | ) | (7,042 | ) | |||||||
Amortization of acquired intangible assets (1) | (167 | ) | (142 | ) | (334 | ) | (284 | ) | |||||||
Total Non-GAAP operating expenses | $ | 18,576 | $ | 16,842 | $ | 37,016 | $ | 33,845 | |||||||
Loss from operations | $ | (8,248 | ) | $ | (7,441 | ) | $ | (15,956 | ) | $ | (16,575 | ) | |||
Stock-based compensation expense | 4,497 | 3,760 | 8,809 | 7,417 | |||||||||||
Amortization of acquired intangible assets (1) | 217 | 192 | 434 | 384 | |||||||||||
Non-GAAP loss from operations | $ | (3,534 | ) | $ | (3,489 | ) | $ | (6,713 | ) | $ | (8,774 | ) | |||
Net loss | $ | (9,130 | ) | $ | (8,344 | ) | $ | (17,251 | ) | $ | (17,747 | ) | |||
Stock-based compensation expense | 4,497 | 3,760 | 8,809 | 7,417 | |||||||||||
Amortization of acquired intangible assets (1) | 217 | 192 | 434 | 384 | |||||||||||
Non-GAAP net loss (2) | $ | (4,416 | ) | $ | (4,392 | ) | $ | (8,008 | ) | $ | (9,946 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.22 | ) | $ | (0.22 | ) | $ | (0.42 | ) | $ | (0.47 | ) | |||
Per share impacts of adjustments to net loss (3) | $ | 0.11 | $ | 0.11 | $ | 0.22 | $ | 0.21 | |||||||
Non-GAAP net loss per share attributable to common stockholders, basic and diluted | $ | (0.11 | ) | $ | (0.11 | ) | $ | (0.20 | ) | $ | (0.26 | ) | |||
Weighted-average shares used in computing per share amounts, basic and diluted | 41,819,427 | 38,476,934 | 41,338,907 | 38,092,996 |
(1) Represents the amortization expenses of our intangible assets attributable to our acquisitions.
(2) Our GAAP tax provision is primarily related to foreign withholding taxes and income tax in profitable foreign jurisdictions. We maintain a full valuation allowance against our deferred tax assets in the US. Accordingly, there is no significant tax impact associated with these Non-GAAP adjustments.
(3) Reflects the aggregate adjustments made to reconcile Non-GAAP net loss to our net loss as noted in the above table, divided by the GAAP diluted weighted average number of shares of the relevant period.
Free Cash Flow
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Net cash (used in) provided by operating activities | $ | (2,485 | ) | $ | 311 | $ | 375 | $ | 788 | ||||||
Less: | |||||||||||||||
Purchase of property and equipment | (355 | ) | (47 | ) | (538 | ) | (243 | ) | |||||||
Free cash flow | $ | (2,840 | ) | $ | 264 | $ | (163 | ) | $ | 545 | |||||
Net cash provided by (used in) investing activities | $ | 705 | $ | (4,357 | ) | $ | 584 | $ | 7,545 | ||||||
Net cash provided by financing activities | $ | 1,508 | $ | 55 | $ | 1,456 | $ | 99 |
